Immunogen Announces Presentations at Aacr Annual Meeting Highlighting Continued Innovation in Adcs
Jun 23, 2022
Bantam Pharmaceutical and Collaborators to Present New Data in Support of its Clinical Candidate BTM-3566 at Third AACR International Meeting - Advances in Malignant Lymphoma
Apr 28, 2022
Immunicom Presents New Data at AACR 2022 of LW-02 Cartridge Immunopheresis Therapy from Ongoing mTNBC Clinical Trial in Chemo-Refractory Patients
Apr 21, 2022
Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting
Apr 20, 2022
Phanes Therapeutics revealed manufacturing validation of its bispecific technology platforms PACbody™ and SPECpair™ at AACR 2022
Apr 13, 2022
NeoImmuneTech Demonstrates NT-I7's Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022
Apr 13, 2022
Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR
Apr 13, 2022
Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022
Apr 13, 2022
OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting
Apr 12, 2022
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with Metastatic Melanoma Presented at the AACR Annual Meeting 2022
Apr 12, 2022
ZielBio to Present New Data Demonstrating Preclinical Efficacy of ZB131 in Cholangiocarcinoma at AACR Annual Meeting 2022
Apr 12, 2022
OncoNano Medicine Announces Positive Preclinical Data for Tumor Specific Delivery with the ON-BOARD™ Platform at AACR 2022 Annual Meeting
Apr 11, 2022
Circle Pharma Announces Presentation at the American Association for Cancer Research 2022 Annual Meeting
Apr 11, 2022
OncXerna Therapeutics Highlights the Xerna™ TME Panel's Prognostic and Predictive Value Across Indications and Therapeutic Classes at the AACR Annual Meeting
Apr 11, 2022
Phosplatin Therapeutics Reports on PT-112's Selective Effects and Immunogenic Cell Death in Human Prostate Cancer Cell Models at the AACR Annual Meeting 2022
Apr 11, 2022
Seneca Therapeutics, Inc. Presents Promising New Preclinical Data Combining its Lead Oncolytic Immunotherapeutic SVV-001 in Combination with Checkpoint Inhibitors at the 2022 Annual AACR Meeting
Apr 11, 2022
PACT Reports New Data on First-of-its-Kind Personalized Neoantigen Platform for Adoptive T Cell Therapies at American Association for Cancer Research (AACR) Annual Meeting 2022
Apr 11, 2022
Vivace Therapeutics Presents New Preclinical Data Highlighting Strong Synergistic Activity for Combination of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annual Meeting 2022
Apr 11, 2022
Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting
Apr 11, 2022
Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022
Apr 11, 2022
Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways
Apr 11, 2022
Linnaeus Therapeutics Announces Presentation of Pre-Clinical Data of LNS8801 at 2022 AACR Annual Meeting
Apr 10, 2022
Gennao Bio Presents Promising New Results from its Gene Monoclonal Antibody (GMAB) Platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Apr 10, 2022
Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK™ Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming
Apr 10, 2022
Triumvira Immunologics to Present Two Posters Covering Ongoing Phase 1/2 Solid Tumor Trial and New Preclinical Gastric Cancer Data at AACR Annual Meeting 2022
Apr 10, 2022
Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming
Apr 9, 2022
PIC Therapeutics to Present Pre-Clinical Data on eIF4E Program to Address Breast Cancer Drug Resistance at AACR Annual Meeting 2022
Apr 8, 2022
Boundless Bio Presents Data on the Novel Discovery of the Association Between Extrachromosomal DNA (ecDNA) and Replication Stress at the American Association for Cancer Research Annual Meeting 2022
Apr 8, 2022
Carisma Therapeutics to Present Engineered Cell Therapy Data at The American Association for Cancer Research Annual Meeting
Apr 8, 2022
HotSpot Therapeutics Presents Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022
Apr 8, 2022
Immunomic Therapeutics Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at the American Association for Cancer Research (AACR) Annual Meeting 2022
Apr 8, 2022
Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2022
Apr 8, 2022
Asher Bio to Unveil Two New Immunotherapy Programs, a CD8+ T Cell Targeted IL-21 and a Cis-Targeted IL-2 for Cell Therapy Augmentation, at AACR Annual Meeting
Apr 8, 2022
Asher Bio to Present New Preclinical Data Demonstrating Differentiated Profile of AB248, its Lead Cis-targeted IL-2 Immunotherapy, at AACR Annual Meeting
Apr 8, 2022
Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Meeting 2022
Apr 8, 2022
NiKang Therapeutics Presents Preclinical Data Highlighting NKT2152's Therapeutic Potential in Clear Cell Renal Cell Carcinoma (ccRCC) and Solid Tumors Beyond ccRCC at AACR Annual Meeting 2022
Apr 8, 2022
Nimbus Therapeutics Presents Preclinical Data on Cbl-b Inhibitor at AACR Annual Meeting
Apr 8, 2022
OncoMyx Presents New Data at AACR 2022 Demonstrating Multi-Armed Myxoma Virus Coordinates Tumor-Killing by Activating Innate and Adaptive Immune Responses
Apr 8, 2022
Orum Therapeutics Presents Preclinical Data at AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1
Apr 8, 2022
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data Supporting the Development of Its Potentially Best-in-Class Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors at the AACR Annual Meeting 2022
Apr 8, 2022
Elpis Biopharmaceuticals Showcases Preclinical Data from its Transformative Multi-functional Immuno-Oncology Programs at 2022 AACR Annual Meeting
Apr 8, 2022
Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Apr 8, 2022
T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting
Apr 8, 2022
Bantam Pharmaceutical and Collaborators to Present New Data in Support of its lead drug BTM-3566 at AACR Annual Meeting 2022
Apr 8, 2022
Iterion Therapeutics Announces Presentation of Three Posters Involving Research into Tegavivint at the AACR 2022 Annual Meeting
Apr 8, 2022
OncoOne Presents Preclinical Proof of Concept Data for its Next-Generation oxMIF-targeted Monoclonal Antibody ON203 at the AACR Annual Meeting
Apr 8, 2022
Orphagen Pharmaceuticals Presents Preclinical Efficacy Data at AACR 2022 on OR-449, a First-in-Class Steroidogenic Factor 1 Inhibitor, for the Treatment of Leydig Cell Tumors
Apr 8, 2022
Tachyon Presents Preclinical Data on the Company's Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting
Apr 8, 2022
OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a Late-Breaking Session at AACR
Apr 8, 2022
Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Modulator, Induces Migration of Immune Effector Cells, Inhibits Tumor Growth as Monotherapy and Boosts Anti-Programmed Death Protein-1 (PD-1) Activity
Apr 8, 2022
iOnctura Presents Data at AACR Demonstrating its Unique Mechanism of Action for Clinical Stage ATX Inhibitor IOA-289
Apr 8, 2022
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
Apr 7, 2022
Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting
Apr 7, 2022
Apexigen Announces That New Data From Phase 2 Trial Evaluating its CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma Will Be Presented at the AACR Annual Meeting 2022
Apr 7, 2022
iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022
Apr 6, 2022
AffyImmune Therapeutics to Present Poster at American Association for Cancer Research Annual Meeting
Apr 5, 2022
Cytonus Therapeutics to Present Preclinical Data for Systemically Delivered Oncolytic Virus Program for Treating Metastatic Cancers at AACR 2022
Apr 5, 2022
Nouscom Announces AACR 2022 Late-Breaking Presentation of Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of MSI-H Solid Tumors
Apr 4, 2022
Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting
Apr 4, 2022
Bright Peak Therapeutics kündigt mehrere Präsentationen auf der Jahrestagung der American Association for Cancer Research (AACR) an
Apr 4, 2022
Elucida Oncology's Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting
Apr 4, 2022
Vivace Therapeutics to Present New Data from Preclinical Combination Studies of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annual Meeting 2022
Mar 31, 2022
Immunomic Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
Mar 30, 2022
Transcenta Announces Presentation of Preclinical Data of TST005 at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Mar 29, 2022
Cytonus Therapeutics to Present Preclinical Data for Cargocyte™ CA-IL-12 for Treating Immune Checkpoint Inhibitor-Resistant Late Stage Metastatic Cancers at AACR 2022
Mar 28, 2022
Actuate Therapeutics Announces Poster Presentations at the 2022 AACR Annual Meeting
Mar 28, 2022
Nimbus Therapeutics to Present Update on Cbl-b Discovery Program at AACR 2022 Annual Meeting
Mar 23, 2022
Virtuoso Therapeutics to Present Preclinical Findings on Two Best-in-Class Bispecific Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Mar 23, 2022
ICHNOS SCIENCES ANNOUNCES PRESENTATION OF ADDITIONAL PRECLINICAL DATA ON ISB 1442 FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA AT AACR 2022 ANNUAL MEETING
Mar 22, 2022
KSQ Therapeutics to Present Data at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Mar 21, 2022
Biond Biologics Announces Oral Presentation for BND-67, an Inhibitor of CD28 Shedding, a Potential Novel Resistance Mechanism to Anti PD-1 Therapy, at the American Association for Cancer Research (AACR) 2022 Annual Meeting USA - English USA - English
Mar 21, 2022
Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022
Mar 17, 2022
Shasqi to Present on SQ3370 and CAPAC Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Mar 16, 2022
Phanes Therapeutics Announces Three Upcoming Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Mar 16, 2022
Cytovia Therapeutics to Present Preclinical Data for iPSC-derived NK Cells and Flex-NK™ Engager Multispecific Antibodies at 2022 AACR Annual Meeting
Mar 16, 2022
Oligon to Present Three Abstracts at AACR 2022 Annual Meeting
Mar 15, 2022
EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual Meeting
Mar 15, 2022
Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022
Mar 10, 2022
NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting
Mar 10, 2022
Phosplatin Therapeutics Presents on PT-112 at the 2022 AACR Annual Meeting: Selective Intracellular Effects Leading to Immunogenic Cell Death (ICD) in Prostate Cancer Cell Models
Mar 10, 2022
OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
Mar 9, 2022
Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2022
Mar 9, 2022
Immune-Onc Therapeutics Announces Preclinical and Clinical Poster Presentations for IO-108, a Novel Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Mar 9, 2022
Seneca Therapeutics Announces Publication of AACR Abstract Demonstrating Systemic Anti-Tumor Immune Response in Syngeneic Pancreatic Murine Model
Mar 9, 2022
Palleon Pharmaceuticals to Present Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase at AACR Annual Meeting
Mar 9, 2022
Myeloid Therapeutics Announces Late-Breaking Presentations on mRNA in-vivo Delivery and ATAK™ CAR Receptors at AACR 2022 Annual Meeting
Mar 9, 2022
Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at AACR Annual Meeting 2022
Mar 9, 2022
Catamaran Bio to Present Preclinical Efficacy Data on Allogeneic Solid Tumor CAR-NK Program at AACR Annual Meeting 2022
Mar 9, 2022
Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
Mar 9, 2022
Frontier Medicines Announces Oral Presentation on Dual-Acting Inhibitors of the Active and Inactive Forms of KRAS G12C at the American Association for Cancer Research (AACR) Annual Meeting
Mar 8, 2022
HotSpot Therapeutics to Present Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022
Mar 8, 2022
Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Mar 8, 2022
Asher Bio to Showcase Continued Progress with Lead Program AB248 and Growing Pipeline of Precisely-Targeted Immunotherapies at AACR Annual Meeting 2022
Mar 8, 2022
Orum Therapeutics to Present Preclinical Data for ORM-5029, a Novel Antibody Neodegrader Conjugate, at the AACR Annual Meeting 2022
Mar 8, 2022
OnQuality Pharmaceuticals to Present Preclinical Data for OQL051, a Novel Chemotherapy-Induced Diarrhea Therapeutic, at AACR
Mar 8, 2022
Gennao Bio Announces Oral Presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Mar 8, 2022
Scorpion Therapeutics to Present Mutant-Selective PI3Kα Program at AACR Annual Meeting 2022
Oct 8, 2021
OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR Virtual Conference on Tumor Immunology and Immunotherapy
Oct 7, 2021
Kineta Presents Preclinical Data on Its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy
Sep 30, 2021
OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy
Sep 28, 2021
Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
Jun 10, 2021
Immunicom Presents Promising Clinical Trial Data at AACR in Late-Stage Breast Cancer Patients Treated with Novel Non-Pharmaceutical Immunotherapy
May 17, 2021
Boundless Bio Announces Educational Session on Extrachromosomal DNA (ecDNA) at the American Association for Cancer Research (AACR) Annual Meeting 2021
May 13, 2021
Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021
May 6, 2021
Istari Oncology Abstracts to be Presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting Reflect Continued Progress in the Clinical Development of PVSRIPO
May 6, 2021
Ribon Therapeutics Announces Upcoming Presentations at the AACR 2021 Virtual Annual Meeting
Apr 29, 2021
Elucida Oncology to Present Preclinical Data on ELU001 at the American Association for Cancer Research Annual Meeting
Apr 19, 2021
AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration
Apr 15, 2021
Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting
Apr 14, 2021
BERG Announces Oncology Pipeline Advancements And Biomarker Developments For Clinical Decision Support In Breast Cancer At AACR
Apr 13, 2021
iTeos Therapeutics gibt beim AACR Annual Meeting 2021 neue vorläufige Daten zur klinischen Aktivität seines Anti-TIGIT-Antikörpers, EOS-448, bekannt
Apr 13, 2021
SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS Test in Ovarian Cancer
Apr 12, 2021
Amphivena Presents Translational Data Highlighting the Cytokine Profile for its Lead Clinical Candidate, AMV564 at the AACR 2021 Virtual Annual Meeting
Apr 12, 2021
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting
Apr 12, 2021
Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021
Apr 10, 2021
Elevation Oncology Announces the Presentation of New Preclinical Data in Pancreatic and Cholangiocarcinoma PDX Models on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling
Apr 10, 2021
Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody Conjugate, TAC-001, at the 2021 Virtual Annual Meeting of the American Association for Cancer Research (AACR)
Apr 10, 2021
iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021
Apr 10, 2021
Boundless Bio Presents Data on the Role of Extrachromosomal DNA (ecDNA) in Mediating Resistance to Targeted Therapies at the American Association for Cancer Research (AACR) Annual Meeting 2021
Apr 10, 2021
Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities
Apr 10, 2021
OncXerna Therapeutics Provides New Results from its Xerna™ RNA-based Biomarker Platform at the AACR Annual Meeting
Apr 10, 2021
ITM Presents Design for Ongoing Phase III COMPETE Trial with n.c.a. 177Lu-Edotreotide at AACR Annual Meeting 2021
Apr 10, 2021
OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune Response
Apr 9, 2021
CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting
Apr 9, 2021
MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment
Apr 9, 2021
Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021
Apr 9, 2021
Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Apr 9, 2021
IN8bio Demonstrates In Vitro Activity of DeltEx DRI CAR-T Cells Against Glioblastoma Multiforme at AACR
Apr 9, 2021
Shanghai Genechem Co., Ltd. (Genechem) gibt die Ernennung von Dr. Eric Rowinsky und Dr. Manuel Hidalgo zum wissenschaftlichen Beirat und die Präsentation von Fachartikeln über Claudin 6 Ab und K-Ras TCR-T auf der AACR 2021 bekannt Deutschland - Deutsch España - español USA - English France - Français
Apr 8, 2021
Volastra Therapeutics Co-founder Samuel Bakhoum to Deliver Plenary Presentation at American Association for Cancer Research Annual Meeting 2021
Apr 8, 2021
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting
Apr 8, 2021
Shanghai Genechem Co., Ltd. (Genechem) Announces appointment of Dr. Eric Rowinsky and Dr. Manuel Hidalgo to Scientific Advisory board, and abstract presentation at AACR 2021 on Claudin 6 Ab and K-Ras TCR-T USA - English España - español Deutschland - Deutsch France - Français
Apr 5, 2021
Teon Therapeutics to Present Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference
Mar 31, 2021
Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021
Mar 23, 2021
GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
Mar 19, 2021
Cygnal Therapeutics to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2021
Mar 15, 2021
Seneca Therapeutics Announces Acceptance of Late Breaking SVV-001 Abstract to American Association for Cancer Research Annual Meeting April 10-15, 2021
Mar 11, 2021
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
Mar 11, 2021
ITM Announces Poster Presentation Outlining the Ongoing Phase III GEP-NET Trial COMPETE at AACR Annual Meeting 2021
Mar 10, 2021
LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting
Mar 10, 2021
PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
Mar 10, 2021
SEngine Precision Medicine to Present Data on Predictive Value of PARIS Test in Ovarian Cancer Patients at 2021 AACR Annual Conference
Feb 22, 2021
Ashvattha Therapeutics to Present at 2021 AACR Virtual Special Conference on Radiation Science and Medicine
Oct 20, 2020
Kineta Presents New Preclinical Data on its VISTA Antagonist Antibodies at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy
Oct 19, 2020
OncoMyx Announces Presentation of Preclinical Data for Novel Oncolytic Virotherapy at AACR Tumor Immunology and Immunotherapy Virtual Conference
Oct 19, 2020
Dr. Sid Kerkar Joins EXUMA Biotech as Vice President Oncology, RandD, Company Presents Data on HER2-Targeting CAR-T at AACR Tumor Immunology and Immunotherapy Conference
Jul 16, 2020
Harbour BioMed Presented Pre-Clinical Data on A Fully Human Anti-CD73 Antibody at AACR Virtual Annual Meeting
Jul 9, 2020
Kronos Bio Reports Positive Results of Preclinical Study of KB-0742, an Investigational CDK9 Inhibitor, Demonstrating Potency, Selectivity and Anti-tumor Activity in Prostate Cancer Model
Jun 23, 2020
InxMed Released Research Data of "FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition" at 2020 AACR Annual Meeting
Jun 22, 2020
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
Jun 22, 2020
EpimAb Biotherapeutics Presents Preclinical Data Characterizing EMB-01 at AACR Virtual Annual Meeting II
Jun 22, 2020
RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting
Jun 22, 2020
RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting
Jun 22, 2020
BERG Announces Presentation Of Multiple Interrogative Biology Platform And Outputs From Multiple Collaborations At AACR
Jun 22, 2020
Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II
Jun 22, 2020
F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting
Jun 22, 2020
Ribon Therapeutics Presents Additional Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and Demonstrates Broad Potential of its Platform at the AACR 2020 Virtual Meeting II
Jun 22, 2020
Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at AACR 2020 Virtual Annual Meeting II
Jun 22, 2020
Silverback Therapeutics to Present Preclinical Data on SBT6050 Demonstrating Potent Activation of Human Myeloid Cells and the Potential for Single Agent Clinical Activity
Jun 22, 2020
iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020
Jun 22, 2020
SEngine Precision Medicine Presents Innovative Data on the CLIA Certified PARIS Test for Oncology Drug Sensitivity and the Future of Functional Precision Medicine at AACR 2020
Jun 22, 2020
Rakuten Medical Presents Data during AACR Characterizing how Illuminox (an Investigational Platform based on Photoimmunotherapy) Induces Cancer Cell Death and Enhances the Immune Response Preclinically
Jun 22, 2020
Shasqi Demonstrates Chemistry-based Platform Produces Local and Systemic Anti-tumor Response in Preclinical Cancer Model
Jun 18, 2020
Sermonix to Present Poster on Lasofoxifene, CDK 4/6 Inhibitor Combination for AACR Virtual Annual Meeting
Jun 16, 2020
Boundless Bio Scientific Co-Founder Paul Mischel to Present at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
Jun 15, 2020
iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020
Jun 11, 2020
Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology
Jun 11, 2020
Immunomic Therapeutics to Present at AACR Virtual Annual Meeting II
Jun 10, 2020
NANOBIOTIX Spinoff Curadigm Validates Novel Nanoprimer Technology in RNA Therapeutics
May 27, 2020
RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting
May 27, 2020
iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
May 21, 2020
Forma Therapeutics Announces Preclinical Data Demonstrating Antitumor Activity of a Potent and Selective Inhibitor of CBP/p300 for Androgen Receptor Positive Cancers to be Presented at the American Association for Cancer Research
May 21, 2020
Tarveda Therapeutics to Present Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting
May 21, 2020
Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II
May 20, 2020
iTeos Therapeutics to Present Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
May 18, 2020
Ashvattha Therapeutics to Present at 2020 AACR Virtual Annual Meeting
May 15, 2020
Vividion Therapeutics to Present Data on Novel Covalent E3 Ligase Engager Supporting Broad Targeted Protein Degradation at 2020 AACR Annual Meeting
May 15, 2020
Silverback Therapeutics™ to Present Preclinical Data from Lead ImmunoTAC™ Candidate, SBT6050, at Upcoming ASCO Virtual Scientific Program and AACR Virtual Annual Meeting
May 15, 2020
Ribon Therapeutics to Present New Preclinical Data on its PARP7 Inhibitor - RBN-2397 - and its Discovery Platform at the Upcoming AACR 2020 Virtual Meeting II
May 15, 2020
Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor With Robust In Vivo Activity
May 15, 2020
SEngine Precision Medicine to Present Data Related to the Predictive Value of PARIS Test, an Organoid-based Drug Response Assay, for Cholangiocarcinoma Patients at 2020 AACR Virtual Meeting Session II
May 14, 2020
Ribon Therapeutics to Present New Preclinical Data at the Upcoming AACR Virtual Annual Meetings
Apr 28, 2020
Gracell Reports Data of First-in-human Clinical Trial for Universal TruUCAR™ GC027 in Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Virtual Annual Meeting
Apr 27, 2020
Tarveda Therapeutics Presents Pharmacokinetic and Tumor Biopsy Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting
Apr 27, 2020
Ribon Therapeutics Presents Preclinical Data from its PARP7 and PARP14 Programs at AACR Virtual Meeting I
Apr 13, 2020
Gracell to Present the First-in-human, Universal TruUCAR™ GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Annual Meeting
Nov 19, 2019
Torque Presents Preclinical Data for Lead Deep-Primed Cellular Immunotherapy Programs at AACR 2019 Special Conference on Tumor Immunology and Immunotherapy
Sep 10, 2019
Linnaeus Therapeutics Scientific Cofounder Presents Preclinical Pancreatic Cancer Data at AACR Pancreas Cancer Meeting
May 20, 2019
Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab's Ability to Increase Immune Cell Activation
May 9, 2019
Rainier Therapeutics Announces Upcoming Oral and Poster Presentation on Vofatamab at AACR Bladder Cancer Conference
May 3, 2019
NeoImmuneTech, Genexine, SNUH and POSTECH researchers Announce Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
May 2, 2019
Immunomic Therapeutics Presents Late-Breaking Preclinical Data on DNA Vaccine ITI-7000 at AACR 2019
Apr 3, 2019
Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
Apr 2, 2019
Actym Therapeutics Will Present Data at the 2019 American Association for Cancer Research Annual Meeting
Apr 2, 2019
ORIC Pharmaceuticals Presents Evidence of Glucocorticoid Receptor-Mediated Cancer Treatment Resistance at the AACR Annual Meeting
Apr 2, 2019
MiNA Therapeutics Presents Pre-Clinical Data Supporting Combination of MTL-CEBPA with Sorafenib and Other Cancer Treatments at AACR
Apr 2, 2019
Aro Biotherapeutics to Present Data on Lead Program, ABX900, at AACR
Apr 1, 2019
IO Biotech Presents Data on an Immunomodulatory CCL22-based Vaccine at the American Association for Cancer Research Annual Meeting 2019
Apr 1, 2019
Torque Presents New Preclinical Data for its Deep-Primed Cellular Immunotherapy Programs at the American Association for Cancer Research (AACR) Annual Meeting
Apr 1, 2019
Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting
Apr 1, 2019
BERG Presents Novel Mechanism Underlying BPM 31510 in Glioblastoma and Identification of Prostate and Pancreatic Cancer Biomarkers at 2019 AACR Meeting
Apr 1, 2019
Apexigen Presents Clinical Data On CD40 Antibody APX005M In Metastatic Melanoma At The AACR Annual Meeting 2019
Apr 1, 2019
Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting
Apr 1, 2019
Nkarta Therapeutics Presents Data at AACR Demonstrating Proprietary NK Cell Engineering and Expansion Technology Enhances Potency and Cytotoxicity of NK Cells
Apr 1, 2019
Preclinical Data Demonstrates the Potential of QED Therapeutics' Infigratinib in Multiple FGFR+ Tumor Types
Apr 1, 2019
Primmune Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019
Apr 1, 2019
Bolt Biotherapeutics Presents Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference
Mar 31, 2019
Apexigen Announces New Clinical Data On APX005M In Combination Therapy For Pancreatic Cancer At The AACR Annual Meeting 2019
Mar 31, 2019
F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies
Mar 29, 2019
Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting
Mar 29, 2019
Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting
Mar 29, 2019
Black Diamond Therapeutics Presents Data From its Program Targeting Oncogenic Allosteric Mutations in EGFR for Glioblastoma as Late Breaker at the American Association for Cancer Research (AACR) Annual Meeting
Mar 29, 2019
Arch Oncology to Present Preclinical Data on Highly-Differentiated Anti-CD47 Antibody AO-176 at the AACR Annual Meeting 2019
Mar 29, 2019
Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR
Mar 29, 2019
Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019
Mar 29, 2019
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
Mar 28, 2019
Yisheng Biopharma Announces Research Presentation of Immuno-Oncology Product at AACR Annual Meeting 2019
Mar 28, 2019
AIVITA Biomedical to Present Biomarker Findings at 2019 AACR Annual Meeting
Mar 28, 2019
Cytonus Therapeutics Announces Poster Presentation at the 2019 American Association for Cancer Research Annual Meeting
Mar 27, 2019
Bio-Thera Solutions Announces Two Poster Presentations at the 2019 AACR Annual Meeting
Mar 27, 2019
Enterome to Present Data on Its Innovative Microbiome-derived Molecular Mimicry Approach to Cancer Immunotherapy at AACR 2019
Mar 26, 2019
Tarveda Therapeutics to Present Nonclinical Data on PEN-221 in Combination with Epigenetic Modulation at the 2019 AACR Annual Meeting
Mar 26, 2019
Integral Molecular to Present Claudin 6 MAbs, a Therapeutic Asset for Solid Tumors, at Annual AACR Conference
Mar 25, 2019
Ascentage Pharma Announces Nine Abstracts To Be Presented at the 2019 American Association for Cancer Research Annual Meeting
Mar 25, 2019
F-star Presents New Data on its Tetravalent Bispecific Antibodies at the AACR 2019 Annual Meeting
Mar 20, 2019
Oncorus Announces Four Presentations at AACR Annual Meeting 2019
Mar 20, 2019
Apexigen Announces Clinical Data Presentations On CD40 Antibody APX005M At The AACR Annual Meeting 2019
Mar 19, 2019
Nurix Therapeutics to Present at 2019 American Association for Cancer Research (AACR) Annual Meeting
Mar 18, 2019
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Mar 6, 2019
Ayala Pharmaceuticals to Present Preclinical Data at AACR for AL101, a Pan-Notch Inhibitor Being Evaluated for Adenoid Cystic Carcinoma
Feb 28, 2019
Sensei Biotherapeutics To Present First Preclinical Data on SNS-723 and Long-Term Clinical Results on SNS-301 Data at The 2019 American Association for Cancer Research (AACR) Annual Meeting
Feb 28, 2019
Immunomic Therapeutics Announces Late-Breaking Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019
Feb 28, 2019
iOnctura Selected for an Oral Presentation at 2019 AACR Annual Meeting
Feb 28, 2019
SQZ Biotech to Present at the American Association for Cancer Research (AACR) 2019 Annual Meeting
Feb 27, 2019
Turning Point Therapeutics to Present Data from Four Studies at AACR Annual Meeting
Feb 27, 2019
Tolero Pharmaceuticals to Present New Data Evaluating Investigational Agents TP-0903 and TP-0184 at AACR Annual Meeting 2019
Feb 27, 2019
Bolt Biotherapeutics To Present Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference
Feb 27, 2019
First Clinical Results Evaluating Allogeneic, Off-The-Shelf, Placental-Derived Cells to be Presented by Celularity at 2019 AACR Annual Meeting
Nov 30, 2018
Turnstone Biologics Unveils Novel Vaccinia Oncolytic Viral Immunotherapy Platform
Nov 26, 2018
Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the AACR Special Conference on Tumor Immunology and Immunotherapy
Oct 23, 2018
Cybrexa Therapeutics to Present First Efficacy and Safety Data From Its Lead Program CBX-12 and Initial Data From CBX-13 at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 18, 2018
Tarveda Therapeutics Presents Data Exploring the Efficacy of PEN-866 in Combination with PARP Inhibitors in Preclinical Models of Human Cancer at the AACR Annual Meeting 2018
May 18, 2018
Rgenix Presents Pre-Clinical Data on RGX-202 at the 2018 AACR Annual Meeting
May 17, 2018
Checkmate Pharmaceuticals Presents Clinical Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
May 17, 2018
amcure Presents Pre-Clinical Anti-tumor and Anti-Metastatic Effects of AMC303 at AACR
May 16, 2018
Rgenix to Present Poster on RGX-202 at the 2018 AACR Annual Meeting
May 12, 2018
iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR
May 11, 2018
ADC Therapeutics to Present Two New Investigational Antibody-Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting
May 11, 2018
Tarveda Therapeutics to Present Preclinical Data on PEN-866 in Combination with PARP Inhibitors at the 2018 AACR Annual Meeting
May 4, 2018
Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and STn+ Myeloid Derived Suppressor Cells at the AACR Annual Meeting 2018
May 3, 2018
Bicycle Therapeutics to Present New BT1718 Data in the "New Drugs on the Horizon" Session at the 2018 American Association for Cancer Research Meeting
Apr 17, 2018
Lycera Presents Clinical Safety and Dose Selection Results for First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 AACR Annual Meeting
Apr 17, 2018
BERG Announces Data Presentations at AACR 2018 Validating Novel Prostate Cancer Biomarkers and Clinical Activity of BPM 31510 Across Several Metabolic Cancer Types
Apr 17, 2018
Torque Presents Preclinical Data at AACR Demonstrating that Deep-Primed IL-15 and Deep-Primed IL-12 Anchored to T Cells are Superior to Systemically Administered IL-15 and IL-12 for Increasing T Cell Infiltration and Tumor Killing Without Systemic Toxicity
Apr 17, 2018
CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of Its Multi-Tyrosine Kinase Inhibitor, CBT-102, at AACR Annual Meeting 2018
Apr 16, 2018
RareCyte introduces the CyteFinder HT instrument at AACR for high throughput slide-based imaging optimized for single cell Liquid Biopsy
Apr 12, 2018
Ascentage Pharma Announces Five Abstracts To Be Presented at the 2018 American Association for Cancer Research Annual Meeting
Apr 12, 2018
Effectiveness of DNAtrix Oncolytic Virus DNX-2440 Armed with OX40L to be Presented at the 2018 Annual Meeting of the American Association for Cancer Research
Apr 10, 2018
Asana BioSciences Announces Presentations of ASN003 (BRAF/PI3K inhibitor) and ASN007 (ERK1/2 inhibitor) at the American Association for Cancer Research Annual Meeting
Apr 9, 2018
GigaGen CEO David Johnson to Present Data from Surge Platform at American Association for Cancer Research Annual Meeting 2018
Apr 5, 2018
Lycera to Present Clinical Results and Supporting Preclinical Data for First-In-Class RORgamma Agonist LYC-55716 at the 2018 AACR Annual Meeting
Mar 28, 2018
Checkmate Pharmaceuticals to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Mar 15, 2018
Oncorus®, Inc., Presents Preclinical Data on Next-Generation Oncolytic Virus Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting
Mar 14, 2018
Atreca to Present at 2018 American Association for Cancer Research Annual Meeting
Dec 5, 2017
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting
May 4, 2017
Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting
May 4, 2017
amcure Presents Preclinical Data on Lead Cancer Compound AMC303 at AACR Annual Meeting
May 4, 2017
Siamab Therapeutics Presents New Preclinical Data for Its Novel Anti-STn Antibodies, Antibody-Drug Conjugates, and Anti-STn Bispecific Antibodies at the AACR Annual Meeting 2017
May 3, 2017
Bicycle Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting
Apr 4, 2017
Cantex Pharmaceuticals, Inc. Announces Poster Presentation at AACR Annual Meeting 2017
Apr 3, 2017
eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017
Apr 3, 2017
BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Mutiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel
Mar 31, 2017
3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
Mar 30, 2017
Antitumor Immunity Triggered by DNAtrix Armed Viruses to be Presented at the 2017 Annual Meeting of the American Association for Cancer Research
Mar 27, 2017
Asana BioSciences Highlights Progress in Its Oncology Portfolio with New Data at AACR 2017 on ASN002 (SYK/JAK inhibitor), ASN003 (BRAF/PI3K inhibitor) and ASN004 (5T4-targeted antibody drug conjugate)
Mar 23, 2017
CORRECTING and REPLACING Siamab Therapeutics to Present New Preclinical Data for its Novel Antibodies and Antibody-Drug Conjugates at the American Association for Cancer Research Annual Meeting 2017
Sep 13, 2016
Siamab Therapeutics Presents Promising Preclinical Data at 2016 AACR Ovarian Cancer Research Symposium
May 20, 2016
Xcovery Presents Data Supporting the Potential Efficacy of X-396 in Patients with ALK+ Non-Small Cell Lung Cancer at the AACR Annual Meeting 2016
May 19, 2016
Peloton Therapeutics, Inc. Presents Positive Preclinical Data on First HIF-2α Inhibitor in Combination with Immuno-oncology Agents at 2016 AACR Annual Meeting
May 12, 2016
Symphogen Initiates Anti-MET Clinical Program and Presents Pre-Clinical Anti-MET Data at Annual AACR Meeting April 18th in New Orleans
May 12, 2016
Xcovery to Present at the AACR Annual Meeting 2016
Apr 19, 2016
Lycera Announces Progress in Immuno-Oncology Program Presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting
Apr 18, 2016
BERG Announces BPM31510 Data Presentations At 2016 AACR Annual Meeting
Apr 14, 2016
Asana BioSciences, LLC to Provide First Presentation of Pre-Clinical Data on its Novel ERK 1/2 Inhibitor Program at the American Association for Cancer Research Annual Meeting
Apr 11, 2016
Results from Five Oncology Collaborations to Showcase RareCyte CTC Liquid Tissue Biopsy Technology at AACR Annual Meeting 2016
Mar 18, 2016
eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting
May 21, 2015
Nimbus Therapeutics Announces Initiation of Clinical Studies for ACC Inhibitor
May 19, 2015
Peloton Therapeutics, Inc. Presents Promising Data on First Inhibitor of HIF-2α for Renal Cell Carcinoma at 2015 AACR Annual Meeting
May 17, 2015
Cavion Collaborators Present Data at AACR
May 16, 2015
PsiOxus Therapeutics to Present Promising New Data on Novel Oncolytic Immunoncology Platform at AACR 2015
May 16, 2015
Intensity Therapeutics, Inc.'s Research Selected for Presentation at the 2015 American Association for Cancer Research Annual Meeting
Apr 20, 2015
Immunocore Announces Positive Clinical Trial Data for Novel First-in-Class Immunotherapy at AACR Annual Meeting 2015
Apr 16, 2015
Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015
Apr 15, 2015
Asana BioSciences to Present Preclinical Data for a Novel Dual Inhibitor of SYK and JAK Family Kinases and a 5T4-Targeted Antibody Drug Conjugate at the AACR Annual Meeting in Philadelphia, April 18-22, 2015
Apr 8, 2015
Immunocore to Present IMCgp100 Clinical Trial Data at AACR Annual Meeting 2015
Mar 19, 2015
Lycera to Present at the 2015 American Association for Cancer Research (AACR) Annual Meeting
May 10, 2013
Symphogen Presents New pan-HER data at Annual AACR Meeting
griffithsomme1998.blogspot.com
Source: https://www.preipopharma.com/tags/aacr
0 Response to "Immunogen Announces Presentations at Aacr Annual Meeting Highlighting Continued Innovation in Adcs"
Post a Comment